Abstract
Cystic fibrosis (CF) is a highly prevalent autosomal recessive disorder that is caused by mutations in the CF transmembrane conductance regulator (CFTR) gene (7q31.2), which encodes the CFTR chloride-anion channel that is expressed in several tissues. Life expectancy has increased significantly over the past few decades due to therapeutic advances and early diagnosis through neonatal screening. However, new complications have been identified, including CF-related diabetes (CFRD). The earliest detectable glycemic abnormality is postprandial hyperglycemia that progresses into fasting hyperglycemia. CFRD is associated with a decline in lung function, impairments in weight gain and growth, pubertal development, and increased morbidity and mortality. Annual screening with oral glucose tolerance test is recommended beginning at the age of 10, and screenings are recommended for any age group during the first 48 h of hospital admission. Fasting plasma glucose levels ≥126 mg/dL (7.0 mmol/L) or 2-h postprandial plasma glucose levels ≥200 mg/dL (11.1 mmol/L) that persist for more than 48 h are diagnostic criteria for CFRD. Under stable health condition, the diagnosis is made when laboratory abnormalities in accordance with the American Diabetes Association criteria are detected for the first time; however, levels of HbA1c <6.5% do not rule out the diagnosis. Treatment for CFRD includes insulin replacement and a hypercaloric and hyperproteic diet that does not restrict carbohydrates, fats or salt, and diabetes self-management education. The most important CFRD complications are nutritional and pulmonary disease deterioration, though the microvascular complications of diabetes have already been described.
Research funding: None declared.
Author contribution: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved its submission.
Informed consent: Informed consent was obtained from all individuals included in this study.
Ethical approval: This is a review article and the ethical statement therefore not required.
Conflict of interest: Authors state no conflict of interest.
References
1. Bell, SC, Mall, MA, Gutierrez, H, Macek, M, Madge, S, Davies, JC, et al. The future of cystic fibrosis care: a global perspective. Lancet Respir Med 2020;8:65–124. https://doi.org/10.1016/S2213-2600(19)30337-6.Search in Google Scholar
2. Sanders, DB, Fink, A. Background and epidemiology. Pediatr Clin North Am 2016;63:567–84. https://doi.org/10.1016/j.pcl.2016.04.001.Search in Google Scholar
3. Raskin, S, Pereira-Ferrari, L, Reis, FC, Abreu, F, Marostica, P, Rozov, T, et al. Incidence of cystic fibrosis in five different states of Brazil as determined by screening of p.F508del, mutation at the CFTR gene in newborns and patients. J Cyst Fibros 2008;7:15–22. https://doi.org/10.1016/j.jcf.2007.03.006.Search in Google Scholar
4. Silva Filho, LV, Castaños, C, Ruíz, HH. Cystic fibrosis in Latin America–Improving the awareness. J Cyst Fibros 2016;15:791–3. https://doi.org/10.1016/j.jcf.2016.05.007.Search in Google Scholar
5. Grupo Brasileiro de Estudos em Fibrose Cística. Registro Brasileiro de Fibrose Cística; 2017. Available from: http://portalgbefc.org.br/wp-content/uploads/2019/12/Registro2017.pdf.Search in Google Scholar
6. Kayani, K, Mohammed, R, Mohiaddin, H. Cystic fibrosis-related diabetes. Front Endocrinol (Lausanne) 2018;9:20. https://doi.org/10.3389/fendo.2018.00020.Search in Google Scholar
7. Moran, A, Dunitz, J, Nathan, B, Saeed, A, Holme, B, Thomas, W. Cystic fibrosis-related diabetes current trends in prevalence, incidence, and mortality. Diabetes Care 2009;32:1626–31. https://doi.org/10.2337/dc09-0586.Search in Google Scholar
8. Onady, GM, Stolfi, A. Insulin and oral agents for managing cystic fibrosis-related diabetes. Cochrane Database Syst Rev 2016;4:CD004730. https://doi.org/10.1002/14651858.CD004730.pub4.Search in Google Scholar
9. Rey, MM, Bonk, MP, Hadjiliadis, D. Cystic fibrosis: emerging understanding and therapies. Annu Rev Med 2019;70:197–210. https://doi.org/10.1146/annurev-med-112717-094536.Search in Google Scholar
10. Marunaka, Y. The mechanistic links between insulin and cystic fibrosis transmembrane conductance regulator (CFTR) Cl- channel. Int J Mol Sci 2017;18:1767–808. https://doi.org/10.3390/ijms18081767.Search in Google Scholar
11. Abensur, AR, Ferreira LVR, L, Vergara, AA, Ribeiro, AF, Riedi, CA, Procianoy, EFA, Adde, FV. Diretrizes Brasileiras de Diagnóstico e Tratamento Da Fibrose Cística. J Bras Pneumol 2017;43:219–45.Search in Google Scholar
12. Banavath, LN, Kumar, R, Dayal, D, Yadav, J, Sachdeva, N, Mathew, JL, et al. Glucose intolerance in children with cystic fibrosis: a developing country’s perspective. J Pediatr Endocrinol Metab 2018;31:1139–46. https://doi.org/10.1515/jpem-2018-0222.Search in Google Scholar
13. Hart, NJ, Aramandla, R, Poffenberger, G, Fayolle, C, Thames, AH, Bautista, A, et al. Cystic fibrosis-related diabetes is caused by islet loss and inflammation. JCI Insight 2018;3:e98240. https://doi.org/10.1172/jci.insight.98240.Search in Google Scholar
14. Granados, A, Chan, CL, Ode, KL, Moheet, A, Moran, A, Holl, R. Cystic fibrosis related diabetes: Pathophysiology, screening and diagnosis. J Cyst Fibros 2019;18:S3–9. https://doi.org/10.1016/j.jcf.2019.08.016.Search in Google Scholar
15. Bogdani, M, Blackman, SM, Ridaura, C, Bellocq, JP, Powers, AC, Aguilar-Bryan, L. Structural abnormalities in islets from very young children with cystic fibrosis may contribute to cystic fibrosis-related diabetes. Sci Rep 2017;7:17231. https://doi.org/10.1038/s41598-017-17404-z.Search in Google Scholar
16. Koivula, FN, McClenaghan, NH, Harper, AG, Kelly, C. Islet-intrinsic effects of CFTR mutation. Diabetologia 2016;59:1350–5. https://doi.org/10.1007/s00125-016-3936-1.Search in Google Scholar
17. Edlund, A, Esguerra, JL, Wendt, A, Flodstrom-Tullberg, M, Eliasson, L. CFTR and Anoctamin 1 (ANO1) contribute to cAMP amplified exocytosis and insulin secretion in human and murine pancreatic-cells. BMC Med 2014;12:87. https://doi.org/10.1186/1741-7015-12-87.Search in Google Scholar
18. Ntimbane, T, Mailhot, G, Spahis, S, Rabasa-Lhoret, R, Kleme, ML, Melloul, D, et al. CFTR silencing in pancreatic b-cells reveals a functional impact on glucose-stimulated insulin secretion and oxidative stress response. Am J Physiol Endocrinol Metab 2016;310:E200–12. https://doi.org/10.1152/ajpendo.00333.2015.Search in Google Scholar
19. Blackman, SM, Commander, CW, Watson, C, Arcara, KM, Strug, LJ, Stonebraker, JR, et al. Genetic modifiers of cystic fibrosis-related diabetes. Diabetes 2013;62:3627–35. https://doi.org/10.2337/db13-0510.Search in Google Scholar
20. Janson, J, Ashley, RH, Harrison, D, McIntyre, S, Butler, PC. The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. Diabetes 1999;48:491–8. https://doi.org/10.2337/diabetes.48.3.491.Search in Google Scholar
21. Kuo, P, Stevens, JE, Russo, A, Maddox, A, Wishart, JM, Jones, KL, et al. Gastric emptying, incretin hormone secretion, and postprandial glycemia in cystic fibrosis-effects of pancreatic enzyme supplementation. J Clin Endocrinol Metab 2011;96:E851–5. https://doi.org/10.1210/jc.2010-2460.Search in Google Scholar
22. Moran, A, Pillay, K, Becker, D, Granados, A, Hameed, S, Acerini, CL. ISPAD Clinical Practice Consensus Guidelines 2018 compendium management of cystic fibrosis related diabetes in children and adolescents. Pediatr Diabetes. 2018;19:64–74. https://doi.org/10.1111/pedi.12732.Search in Google Scholar
23. Moran, A, Becker, D, Casella, SJ, Gottlieb, PA, Kirkman, MS, Marshall, BC, et al. Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes: a technical review. Diabetes Care 2010;33:2677–83. https://doi.org/10.2337/dc10-1279.Search in Google Scholar
24. Boudreau, V, Coriati, A, Desjardins, K, Rabasa-Lhoret, R. Glycated hemoglobin cannot yet be proposed as a screening tool for cystic fibrosis related diabetes. J Cyst Fibros 2016;15:258–60. https://doi.org/10.1016/j.jcf.2016.02.005.Search in Google Scholar
25. Chan, CL, Hope, E, Thurston, J, Vigers, T, Pyle, L, Zeitler, PS, et al. Hemoglobin A1c accurately predicts continuous glucose monitoring-derived average glucose in youth and young adults with cystic fibrosis. Diabetes Care 2018;41:1406–13. https://doi.org/10.2337/dc17-2419.Search in Google Scholar
26. O’Riordan, SM, Hindmarsh, P, Hill, NR, Matthews, DR, George, S, Greally, P, et al. Vali-dation of continuous glucose monitoring in children and adolescents with cystic fibrosis: a prospective cohort study. Diabetes Care 2009;32:1020–2. https://doi.org/10.2337/dc08-1925.Search in Google Scholar
27. Franzese, A, Valerio, G, Buono, P, Spagnuolo, MI, Sepe, A, Mozzillo, E, et al. Continuous glucose monitoring system in the screening of early glucose derangements in children and adolescents with cystic fibrosis. J Pediatr Endocrinol Metab 2008;21:109–16. https://doi.org/10.1515/jpem.2008.21.2.109.Search in Google Scholar
28. Clemente León, M, Bilbao Gassó, L, Moreno-Galdó, A, Campos Martorrell, A, Gartner Tizzano, S, Yeste Fernández, D, et al. Oral glucose tolerance test and continuous glucose monitoring to assess diabetes development in cystic fibrosis patients. Endocrinol Diabetes Nutr 2018;65:45–51. https://doi.org/10.1016/j.endien.2018.01.001.Search in Google Scholar
29. Mainguy, C, Bellon, G, Delaup, V, Ginoux, T, Kassai-Koupai, B, Mazur, S, et al. Sensitivity and specificity of different methods for cystic fibrosis-related diabetes screening: is the oral glucose tolerance test still the standard? J Pediatr Endocrinol Metab 2017;30:27–35. https://doi.org/10.1515/jpem-2016-0184.Search in Google Scholar
30. Chan, CL, Ode, KL, Granados, A, Moheet, A, Moran, A, Hameed, S. Continuous glucose monitoring in cystic fibrosis - A practical guide. J Cyst Fibros 2019;18:S25–31. https://doi.org/10.1016/j.jcf.2019.08.025.Search in Google Scholar
31. Ode, KL, Chan, CL, Granados, A, Moheet, A, Moran, A, Brennan, AL. Cystic fibrosis related diabetes: Medical management. J Cyst Fibros 2019;18:S10–18. https://doi.org/10.1016/j.jcf.2019.08.003.Search in Google Scholar
32. Sunni, M, Bellin, MD, Moran, A. Exogenous insulin requirements do not differ between youth and adults with cystic fibrosis related diabetes. Pediatr Diabetes 2013;14(4):295–8. https://doi.org/10.1111/pedi.1201.Search in Google Scholar
33. American Diabetes Association. 13. Children and adolescents: standards of medical care in diabetes-2019. Diabetes Care 2019;42:S139–47.10.2337/dc19-S013Search in Google Scholar
34. Mauch, RM, Pezzo Kmit, AH, Marson, FAL, Levy, CE, Barros-Filho, AA, Ribeiro, JD. Association of growth and nutritional parameters with pulmonary function in cystic fibrosis: a literature review. Rev Paul Pediatr. 2016;34:503–9. https://doi.org/10.1016/j.rppede.2016.02.001.Search in Google Scholar
35. Birch, L, Lithander, FE, Hewer, SL, Harriman, K, Hamilton-Shield, J, Perry, R. Dietary interventions for managing glucose abnormalities in cystic fibrosis. Syst Rev 2018;7:98. https://doi.org/10.1186/s13643-018-0757-y.Search in Google Scholar
36. Ballmann, M, Hubert, D, Assael, BM, Staab, D, Hebestreit, A, Naehrlich, L, et al. Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol 2018;6:114–21. https://doi.org/10.1016/s2213-8587(17)30400-x.Search in Google Scholar
37. Geyer, MC, Sullivan, T, Tai, A, Morton, JM, Edwards, S, Martin, AJ, et al. Exenatide corrects postprandial hyperglycaemia in young people with cystic fibrosis and impaired glucose tolerance: a randomized crossover trial. Diabetes Obes Metab 2019;21:700–4. https://doi.org/10.1111/dom.13544.Search in Google Scholar
38. Gentzsch, M, Mall, MA. Ion channel modulators in cystic fibrosis. Chest 2018;154:383–93. https://doi.org/10.1016/j.chest.2018.04.036.Search in Google Scholar
39. Ramsey, BW, Davies, J, McElvaney, NG, Tullis, E, Bell, SC, Dřevínek, P, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011;365:1663–72. https://doi.org/10.1056/nejmoa1105185.Search in Google Scholar
40. Rey, MM, Bonk, MP, Hadjiliadis, D. Cystic fibrosis: emerging understanding and therapies. Annu Rev Med 2019;70:197–210. https://doi.org/10.1146/annurev-med-112717-094536.Search in Google Scholar
41. Wainwright, CE, Elborn, JS, Ramsey, BW, Marigowda, G, Huang, X, Cipolli, M, et al. Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med 2015;373:220–31. https://doi.org/10.1056/nejmoa1409547.Search in Google Scholar
42. Boyle, MP, Bell, SC, Konstan, MW, McColley, SA, Rowe, SM, Rietschel, E, et al. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med 2014;2:527–38. https://doi.org/10.1016/s2213-2600(14)70132-8.Search in Google Scholar
43. Taylor-Cousar, JL, Munck, A, McKone, EF, van der Ent, CK, Moeller, A, Simard, C, et al. Tezacaftor–ivacaftor in patients with cystic fibrosis homozygous for Phe508del. N Engl J Med 2017;377:2013–23. https://doi.org/10.1056/nejmoa1709846.Search in Google Scholar
44. Donaldson, SH, Pilewski, JM, Griese, M, Cooke, J, Viswanathan, L, Tullis, E, et al. Tezacaftor/ivacaftor in subjects with cystic fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR. Am J Respir Crit Care Med 2018;197:214–24. https://doi.org/10.1164/rccm.201704-0717oc.Search in Google Scholar
45. Gentzsch, M, Mall, MA. Ion channel modulators in cystic fibrosis. Chest 2018;154:383–93. https://doi.org/10.1016/j.chest.2018.04.036.Search in Google Scholar
46. Bellin, MD, Laguna, T, Leschyshyn, J, Regelmann, W, Dunitz, J, Billings, J, et al. Insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR: a small pilot study. Pediatr Diabetes 2013;14:417–21. https://doi.org/10.1111/pedi.12026.Search in Google Scholar
47. Kelly, A, De Leon, DD, Sheikh, S, Camburn, D, Kubrak, C, Peleckis, AJ, et al. Islet hor-mone and incretin secretion in cystic fibrosis after four months of Ivacaftor therapy. Am J Respir Crit Care Med 2019;199:342–51. https://doi.org/10.1164/rccm.201806-1018oc.Search in Google Scholar
48. Moheet, A, Moran, A. Pharmacological management of cystic fibrosis related diabetes. Expert Rev Clin Pharmacol 2018;11:185–91. https://doi.org/10.1080/17512433.2018.1421065.Search in Google Scholar
49. Lewis, C, Blackman, SM, Nelson, A, Oberdorfer, E, Wells, D, Dunitz, J, et al. Diabetes-related mortality in adults with cys-tic fibrosis. Role of genotype and sex. Am J Respir Crit Care Med 2015;191:194–200. https://doi.org/10.1164/rccm.201403-0576oc.Search in Google Scholar
50. Mauch, RM, Pezzo Kmit, AH, Marson, FAL, Levy, CE, Barros-Filho, AA, Ribeiro, JD. Association of growth and nutritional parameters with pulmonary function in cystic fibrosis: a literature review. Rev Paul Pediatr 2016;34: 503–9. https://doi.org/10.1016/j.rppede.2016.02.001.Search in Google Scholar
51. Terliesner, N, Vogel, M, Steighardt, A, Gausche, R, Henn, C, Hentschel, J, et al. Cystic-fibrosis related-diabetes (CFRD) is preceded by and associated with growth failure and deteriorating lung function. J Pediatr Endocrinol Metab 2017;30:815–21. https://doi.org/10.1515/jpem-2017-0005.Search in Google Scholar
52. Yoon, JC. Evolving mechanistic views and emerging therapeutic strategies for cystic fibrosis–related diabetes. J Endocr Soc 2017;1:1386–400. https://doi.org/10.1210/js.2017-00362.Search in Google Scholar
53. Hunt, WR, Helfman, BR, McCarty, NA, Hansen, JM. Advanced glycation end products are elevated in cystic fibrosis-related diabetes and correlate with worse lung function. J Cyst Fibros 2016;15(5):681–8. https://doi.org/10.1016/j.jcf.2015.12.011.Search in Google Scholar
54. Scheuing, N, Badenhoop, K, Borkenstein, M, Konrad, K, Lilienthal, E, Laubner, K, et al. Why is insulin pump treatment rarely used in adolescents and young adults with cystic fibrosis-related diabetes? Pediatr Diabetes 2015;16:10–5. https://doi.org/10.1111/pedi.12158.Search in Google Scholar
55. Piechowiak, K, Trippenbach-Dulska, H, Walicka-Serzysko, K. The course of glucose intolerance in children with cystic fibrosis: a retrospective study-preliminary report. Dev Period Med 2015;19:80–91.Search in Google Scholar
56. Lonabaugh, KP, O’Neal, KS, McIntosh, H, Condren, M. Cystic fibrosis-related education: are we meeting patient and caregiver expectations? Patient Educ Couns 2018;101:1865–70. https://doi.org/10.1016/j.pec.2018.06.004.Search in Google Scholar
© 2020 Walter de Gruyter GmbH, Berlin/Boston
